Dark Horse Consulting

Executive Summary

Dark Horse Consulting Group (DHC) is a specialized consulting firm providing strategic and technical expertise across the entire development lifecycle for biotherapeutics, with a focus on advanced modalities such as cell and gene therapies (CGT), biologics, and regenerative medicine. Founded in 2012 and headquartered in Boulder, Colorado, DHC serves biopharma companies, technology providers, and investors. Through its core entity and acquired divisions, BioTechLogic and Converge Consulting, the firm offers comprehensive support from CMC to commercial launch, positioning itself as a key partner in the rapidly evolving CGT space. Recent acquisitions have strengthened DHC's end-to-end capabilities, enabling it to capture greater market share as the demand for specialized CGT development expertise grows. The CGT market is projected to expand significantly over the next decade, driven by regulatory advancements and increasing pipeline activity. DHC's deep domain knowledge and integrated service model make it well-positioned to benefit from this trend. However, as a private consulting firm, its financials are not publicly disclosed, and growth is tied to overall biopharma R&D spending.

Upcoming Catalysts (preview)

• Q3 2026Full Integration of BioTechLogic and Converge Consulting to Unified Platform80% success
• Q4 2026Major Engagement Win with Top 20 Biotech for CGT Development Program50% success
• Q2 2027Launch of Dedicated Digital Health and Drug Delivery Consulting Practice40% success